Pancap

Name

Pancap

Legal name

Pancap Pharma Inc.

Website

https://pancapinc.com

Company type

Private

Founded year

1993

Operating status

Operating

Headcount range

11–50 employees

Ownership category

akta.pro rank

Product category

Pharmaceutical Contract Manufacturing

akta.pro primary industry

Primary Care & General Medicine Pharmaceuticals (HLAIAAAA)

Keywords

• Digestive enzyme supplements
• Pharmaceutical contract manufacturing
• Delayed release enzymes
• GMP dietary supplements
• Pancreatic enzyme products

Headquarters

HQ city

Markham

HQ country

Canada

HQ region

North America

Offices2 records

Markets served

GTM type

B2B and B2C

Offering type

Hardware or Manufacturing

Cost components

Supply Chain, Operations, Personnel, Technology or R&D, Infrastructure, Marketing or Sales

Revenue model

1. ZYMPAL Dietary Supplement Sales: Direct-to-consumer sales of ZYMPAL pancreatic digestive enzyme supplement through Amazon.com marketplace. Product sold in two dosage strengths with 50 capsules per container.

Pricing tiers

Go-to-market motion2 records

Distribution channels1 record

Marketing channels2 records

Core offering

Pancap Pharma manufactures and sells ZYMPAL, a pancreatic digestive enzyme dietary supplement that uses proprietary enteric-coated microspheres to deliver protease, amylase, and lipase to the small intestine. The product is offered in two dosage strengths (10,000 and 20,000 Lipase USP Units) and is sold directly to consumers through Amazon.com. In parallel, Pancap offers GMP-compliant contract manufacturing and co-development services for delayed release pancreatic enzyme products serving both dietary supplement and prescription markets.

Product overview

Pancap offers a single product offering called ZYMPAL, a pancreatic digestive enzyme dietary supplement. ZYMPAL is available in two dosage strengths: 10,000 Lipase USP Units and 20,000 Lipase USP Units. The product features a proprietary Targeted Delivery System using enteric-coated microspheres that protect enzymes from stomach acid and deliver them to the small intestine. Both dosage variants contain pancrelipase of porcine origin with corresponding amounts of lipase, amylase, and protease enzymes.

Differentiator

Problem solved

Functional benefit

Brands

• ZYMPAL: Pancreatic digestive enzyme dietary supplement with targeted delivery system, available in 10,000 and 20,000 Lipase USP Unit dosage strengths.

Products and services

• ZYMPAL 10,000 Lipase USP Units A lower-dose pancreatic digestive enzyme dietary supplement containing 150 mg pancrelipase (10,000 USP lipase, 37,000 USP amylase, 27,000 USP protease) delivered via enteric-coated microspheres to the small intestine. Sold to adults over 18 experiencing mild digestive discomfort, through Amazon.com.
• ZYMPAL 20,000 Lipase USP Units A higher-dose pancreatic digestive enzyme dietary supplement containing 300 mg pancrelipase (20,000 USP lipase, 80,000 USP amylase, 55,000 USP protease) delivered via enteric-coated microspheres for enhanced nutrient absorption. Sold to adults over 18 seeking stronger digestive support, through Amazon.com.
• Contract Manufacturing and Co-Development of Delayed Release Pancreatic Enzyme Products B2B service offering GMP-compliant contract manufacturing and co-development partnerships for proprietary development programs and delayed release pancreatic enzyme products serving the dietary supplement and prescription markets. Targets pharmaceutical and dietary supplement manufacturers.

Quantifiable outcome

• Improves nutrient absorption efficiency in the small intestine where most chemical digestion occurs
• +1 more outcomes

Segments2 records

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Partnerships

One partnership is on record.

• Co-development Partners (unspecified)coreStrategic or Co-development PartnerPancap Pharma welcomes co-development partnerships for proprietary development programs and for co-development of delayed release pancreatic enzyme products. The company offers its manufacturing capabilities, GMP-compliant facilities, and delayed release technology expertise for partnership opportunities.

Scale indicators3 records

Recent moves5 records

Expansion highlights4 records

Direct peers

• Integrative Therapeutics: Integrative Therapeutics is a practitioner-channel digestive enzyme supplement brand offering products like Similase and Pancreatic Enzyme formulas. Comparable to ZYMPAL because it shares the digestive enzyme supplement category, USP-style potency standards, and similar target use cases.
• Enzymedica: Enzymedica is a leading US-based digestive enzyme supplement brand selling DTC and through retail. Comparable to ZYMPAL because it markets branded digestive enzyme products to consumers with similar use cases (bloating, digestion support), making it a direct competitor in the same shelf space.
• Pure Encapsulations (Atrium Innovations): Pure Encapsulations is a premium practitioner-channel supplement brand offering digestive enzyme formulations. Comparable to ZYMPAL because it targets the same digestive health consumer with branded enzyme supplements, but reaches them through healthcare practitioners rather than Amazon.

Emerging players

• Vitakem: Vitakem is a smaller US-based supplement contract manufacturer offering custom formulation and GMP manufacturing. Comparable to Pancap's CDMO arm because it competes for outsourced dietary supplement manufacturing contracts, though with broader category scope beyond enzymes.
• CapsCanada (Kymanox): CapsCanada is a North American manufacturer of two-piece hard gelatin capsules including enteric-coated versions. Comparable to Pancap because it supplies the underlying capsule and coating technology used in delayed-release oral dosage forms, making it an enabling peer rather than direct competitor.

Broad incumbents

• Organon (Zenpep): Organon (from Nestlé Health Science spinoff) markets Zenpep, another leading prescription pancrelipase product. Comparable to Pancap because it shares the same USP Pancrelipase Delayed Release monograph standard and addresses similar enzyme delivery challenges, but at prescription scale.
• NOW Foods: NOW Foods is a large US supplement manufacturer and brand with a deep digestive enzyme product line. Comparable to Pancap because it competes head-to-head with ZYMPAL in the digestive enzyme supplement category while also contract manufacturing for other brands.
• Patheon (Thermo Fisher Scientific): Patheon, now part of Thermo Fisher, is one of the largest pharmaceutical CDMOs offering oral solid dose manufacturing. Comparable to Pancap's contract manufacturing business because it bids on the same outsourced pharma projects, although with significantly broader capabilities and global scale.
• Catalent: Catalent is a global contract development and manufacturing organization (CDMO) with pharmaceutical softgel and oral dose capabilities. Comparable to Pancap's contract manufacturing arm because it competes for outsourced pharmaceutical manufacturing programs, though at a much larger scale and broader scope.
• AbbVie (CREON): AbbVie markets CREON, the leading pancreatic enzyme replacement therapy (PERT) for exocrine pancreatic insufficiency. Comparable to Pancap because both operate in the pancrelipase/pancreatic enzyme space, although CREON is a prescription blockbuster versus Pancap's supplement positioning.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights6 records

Customer concentration

• LinkedInlinkedin.com/company/pancap-pharma-inc

Compliance3 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Pancap